Dr. Yardley on the Results of the APT and APHINITY Trials for HER2+ Breast Cancer

Denise Yardley, MD
Published: Friday, Jul 07, 2017



Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the results of the APT and APHINITY trials for patients with HER2-positive breast cancer.

The durable response from the APT trial at 5 and 7 years has shown that patients have continued to see benefits, explains Yardley. According to Yardley, this is changing the dynamic of HER2-positive breast cancer.

Additionally, the magnitude of benefit from the addition of trastuzumab (Herceptin) in the APHINITY trial has been tremendous and continues to reduce a patient’s risk for recurrence, states Yardley.
 
SELECTED
LANGUAGE


Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the results of the APT and APHINITY trials for patients with HER2-positive breast cancer.

The durable response from the APT trial at 5 and 7 years has shown that patients have continued to see benefits, explains Yardley. According to Yardley, this is changing the dynamic of HER2-positive breast cancer.

Additionally, the magnitude of benefit from the addition of trastuzumab (Herceptin) in the APHINITY trial has been tremendous and continues to reduce a patient’s risk for recurrence, states Yardley.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x